First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Accent Therapeutics
Mirati Therapeutics Inc.
Baylor Research Institute
Pheon Therapeutics
Novartis
Takeda
Tempus AI
NuCana plc
Institut Bergonié
Academic and Community Cancer Research United
Eli Lilly and Company
Alaunos Therapeutics
Weill Medical College of Cornell University
Swiss Cancer Institute
Mirati Therapeutics Inc.
University of Iowa
Washington University School of Medicine
Peter MacCallum Cancer Centre, Australia
Mayo Clinic
Alliance for Clinical Trials in Oncology
Mirati Therapeutics Inc.
University of Kentucky
NantCell, Inc.
NextCure, Inc.
Columbia University
Ohio State University Comprehensive Cancer Center
ADC Therapeutics S.A.
Columbia University
Milton S. Hershey Medical Center
HiberCell, Inc.
Virginia Commonwealth University
Gilead Sciences
Stanford University
Ludwig Institute for Cancer Research
pharmaand GmbH
NSABP Foundation Inc
Roswell Park Cancer Institute
Eastern Cooperative Oncology Group
Eisai Inc.
Masonic Cancer Center, University of Minnesota
Northwell Health
Brown University
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Imunon
Royal Marsden NHS Foundation Trust
Icahn School of Medicine at Mount Sinai
Washington University School of Medicine
Hadassah Medical Organization
Sun Yat-sen University
Assistance Publique - Hôpitaux de Paris